NCT06312761View on ClinicalTrials.gov

Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hypogonadism, Male

Interventions

DRUG

Relugolix 120Mg Tab

Relugolix 120 mg single dose - All subjects

DIETARY_SUPPLEMENT

Curcumin

Curcumin 630 mg single dose

DRUG

Testosterone Undecanoate 237 MG Oral Capsule

All Listed Sponsors

collaborator

Washington State University

OTHER

lead

University of Washington

OTHER

NCT06312761 - Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 | Biotech Hunter | Biotech Hunter